Zydus Lifesciences Soars with 30% Profit Surge in Q3

Zydus Lifesciences reported a 30% increase in consolidated net profit for Q3 2024, reaching Rs 1,023 crore. Revenue rose to Rs 5,269 crore, driven by robust sales in domestic and US markets. The company aims for double-digit growth and improved profitability through strategic initiatives and product portfolio management.

Zydus Lifesciences announced a notable 30% rise in consolidated net profit, reaching Rs 1,023 crore for the third quarter ending December 31, 2024. This boost was attributed to strong sales performances within both domestic and US markets.

Compared to the previous fiscal's October-December quarter, where a net profit of Rs 790 crore was recorded, the firm showed significant improvement. The company's revenue from operations escalated to Rs 5,269 crore in the third quarter, compared to Rs 4,505 crore from the same period last year, according to an official statement.

Sharvil Patel, Managing Director, emphasized the strategic focus on patient centricity and quality, as well as leveraging global portfolios, to sustain future growth. Despite a 1.79% drop in share price on BSE, the company remains positive about achieving double-digit growth and enhanced profitability for fiscal year 2025.